You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Baxter
Merck
Boehringer Ingelheim
AstraZeneca

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Patent: 9,896,480

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,896,480
Title:Integrin receptor antagonists and their methods of use
Abstract: Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH--CH(CH.sub.2--SO.sub.3H)COOH or Arg-Gly-NH--CH(CH.sub.2--SO.sub.3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to .alpha..sub.5.beta..sub.1-Integrin, .alpha..sub.v.beta..sub.3-Integrin and .alpha..sub.v.beta..sub.5-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.
Inventor(s): Mackel; Michael John (Portland, OR), Park; John Y. (Santa Ana, CA), Karageozian; Hampar L. (San Juan Capistrano, CA), Karageozian; Vicken H. (San Juan Capistrano, CA)
Assignee: Allegro Pharmaceuticals, Inc. (San Juan Capistrano, CA)
Application Number:13/467,995
Patent Claims:see list of patent claims

Details for Patent 9,896,480

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Regeneron Pharmaceuticals EYLEA aflibercept INJECTABLE; INJECTION 125387 001 2011-11-18   Start Trial Allegro Pharmaceuticals, Inc. (San Juan Capistrano, CA) 2029-11-10 RX search
Genentech LUCENTIS ranibizumab INJECTABLE; INJECTION 125156 001 2006-06-30   Start Trial Allegro Pharmaceuticals, Inc. (San Juan Capistrano, CA) 2029-11-10 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Allegro Pharmaceuticals, Inc. (San Juan Capistrano, CA) 2029-11-10 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Allegro Pharmaceuticals, Inc. (San Juan Capistrano, CA) 2029-11-10 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Merck
Colorcon
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.